Table 5.
Immunological parameters of 84 patients with NTM lung disease and 47 non-NTM BE patients
| NTM lung disease patients N = 84 | Non-NTM BE patients N = 47 | P value | ||
|---|---|---|---|---|
| Positive RF |
5 (6.0%) |
11 (23.4%) |
0.01 |
|
| RF level (0–9.9 IU/mL)*, median (IQR) |
16 (15,92) |
18 (15,86) |
0.88 |
|
| Positive FANA |
11 (13.1%) |
2 (4.3%) |
0.14 |
|
| FANA titer, median (IQR) |
40 (40,50) |
60 (40,80) |
0.74 |
|
| Positive IGRA |
38 (45.2%) |
26 (55.3%) |
0.28 |
|
| Patients with low level of immunoglobulins |
|
|
|
|
| IgG |
(700–1700 mg/dL)* |
1 (1.2%) |
0 (0%) |
1.00 |
| IgA |
(90–400 mg/dL)* |
3 (3.6%) |
0 (0%) |
0.55 |
| IgM |
(45–230 mg/dL)* |
6 (7.1%) |
4 (8.5%) |
0.75 |
| C3 |
(70–150 mg/dL)* |
1 (1.2%) |
1 (2.1%) |
1.00 |
| C4 | (10–35 mg/dL)* | 1 (1.2%) | 1 (2.1%) | 1.00 |
Abbreviations: FANA fluorescent antinuclear antibody test, IGRA IFN-γ release assay, RF rheumatoid factor, NTM nontuberculous mycobacteria, BE bronchiectasis, IQR interquartile range.
*Normal ranges.